Forte Biosciences Q2 EPS $(0.27) Misses $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Forte Biosciences (NASDAQ:FBRX) reported a Q2 EPS loss of $(0.27), missing the analyst consensus estimate of $(0.17) by 58.82%. This represents a 35.71% improvement over the $(0.42) loss per share from the same period last year.
August 14, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Forte Biosciences reported a Q2 EPS loss of $(0.27), missing the analyst consensus estimate of $(0.17) by 58.82%. Despite the miss, the loss per share improved by 35.71% compared to the same period last year.
The significant miss on EPS estimates is likely to negatively impact the stock price in the short term. However, the year-over-year improvement in losses may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100